Japan cancer of the prostate risk assessment for combined androgen blockade including bicalutamide

Clinical application and validation

Yasuhide Kitagawa, Shiro Hinotsu, Kazuyoshi Shigehara, Kazufumi Nakashima, Shohei Kawaguchi, Hiroshi Yaegashi, Atsushi Mizokami, Hideyuki Akaza, Mikio Namiki

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives: The Japan Cancer of the Prostate Risk Assessment was developed as a risk stratification instrument for patients undergoing primary androgen deprivation therapy. However, there have been no studies to validate the accuracy of the Japan Cancer of the Prostate Risk Assessment in predicting clinical outcomes. We examined whether the clinical outcomes of patients treated with combined androgen blockade could be stratified using the Japan Cancer of the Prostate Risk Assessment. Methods: A total of 319 patients with prostate cancer treated with luteinizing hormone-releasing hormone agonist plus bicalutamide were included in this analysis. Progression-free survival, cause-specific survival and overall survival were compared among patients divided according to the prostate-specific antigen level at diagnosis, Gleason score on biopsy specimens, tumor-nodes-metastasis classification and Japan Cancer of the Prostate Risk Assessment score. Results: The median age of the patients was 75years, and the median prostate-specific antigen at diagnosis was 25.4ng/mL. A total of 102 patients (32.0%) had lymph node and/or distant metastases. On univariate analysis, the factors adopted in the Japan Cancer of the Prostate Risk Assessment points were significant predictors of progression-free survival. On multivariate analysis, clinical T stage and M stage were significant predictors of progression-free survival. The probabilities of progression-free survival and cause-specific survival were significantly different among the groups categorized according to the Japan Cancer of the Prostate Risk Assessment risk strata. The probability of overall survival in the low-risk group was higher than in the other groups. Conclusions: The progression-free survival, cause-specific survival and overall survival of prostate cancer patients treated by combined androgen blockade with bicalutamide were stratified by the Japan Cancer of the Prostate Risk Assessment. The Japan Cancer of the Prostate Risk Assessment score is clinically useful as a predictor of the prognosis of prostate cancer treated with combined androgen blockade.

Original languageEnglish
Pages (from-to)708-714
Number of pages7
JournalInternational Journal of Urology
Volume20
Issue number7
DOIs
Publication statusPublished - Jul 2013
Externally publishedYes

Fingerprint

Androgens
Prostatic Neoplasms
Japan
Disease-Free Survival
Survival
Prostate-Specific Antigen
bicalutamide
Neoplasm Metastasis
Neoplasm Grading
Gonadotropin-Releasing Hormone
Multivariate Analysis
Lymph Nodes
Biopsy

Keywords

  • Combined androgen blockade
  • Outcome prediction
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Japan cancer of the prostate risk assessment for combined androgen blockade including bicalutamide : Clinical application and validation. / Kitagawa, Yasuhide; Hinotsu, Shiro; Shigehara, Kazuyoshi; Nakashima, Kazufumi; Kawaguchi, Shohei; Yaegashi, Hiroshi; Mizokami, Atsushi; Akaza, Hideyuki; Namiki, Mikio.

In: International Journal of Urology, Vol. 20, No. 7, 07.2013, p. 708-714.

Research output: Contribution to journalArticle

Kitagawa, Y, Hinotsu, S, Shigehara, K, Nakashima, K, Kawaguchi, S, Yaegashi, H, Mizokami, A, Akaza, H & Namiki, M 2013, 'Japan cancer of the prostate risk assessment for combined androgen blockade including bicalutamide: Clinical application and validation', International Journal of Urology, vol. 20, no. 7, pp. 708-714. https://doi.org/10.1111/iju.12037
Kitagawa, Yasuhide ; Hinotsu, Shiro ; Shigehara, Kazuyoshi ; Nakashima, Kazufumi ; Kawaguchi, Shohei ; Yaegashi, Hiroshi ; Mizokami, Atsushi ; Akaza, Hideyuki ; Namiki, Mikio. / Japan cancer of the prostate risk assessment for combined androgen blockade including bicalutamide : Clinical application and validation. In: International Journal of Urology. 2013 ; Vol. 20, No. 7. pp. 708-714.
@article{fe1db95715e740f9abfca6883babe723,
title = "Japan cancer of the prostate risk assessment for combined androgen blockade including bicalutamide: Clinical application and validation",
abstract = "Objectives: The Japan Cancer of the Prostate Risk Assessment was developed as a risk stratification instrument for patients undergoing primary androgen deprivation therapy. However, there have been no studies to validate the accuracy of the Japan Cancer of the Prostate Risk Assessment in predicting clinical outcomes. We examined whether the clinical outcomes of patients treated with combined androgen blockade could be stratified using the Japan Cancer of the Prostate Risk Assessment. Methods: A total of 319 patients with prostate cancer treated with luteinizing hormone-releasing hormone agonist plus bicalutamide were included in this analysis. Progression-free survival, cause-specific survival and overall survival were compared among patients divided according to the prostate-specific antigen level at diagnosis, Gleason score on biopsy specimens, tumor-nodes-metastasis classification and Japan Cancer of the Prostate Risk Assessment score. Results: The median age of the patients was 75years, and the median prostate-specific antigen at diagnosis was 25.4ng/mL. A total of 102 patients (32.0{\%}) had lymph node and/or distant metastases. On univariate analysis, the factors adopted in the Japan Cancer of the Prostate Risk Assessment points were significant predictors of progression-free survival. On multivariate analysis, clinical T stage and M stage were significant predictors of progression-free survival. The probabilities of progression-free survival and cause-specific survival were significantly different among the groups categorized according to the Japan Cancer of the Prostate Risk Assessment risk strata. The probability of overall survival in the low-risk group was higher than in the other groups. Conclusions: The progression-free survival, cause-specific survival and overall survival of prostate cancer patients treated by combined androgen blockade with bicalutamide were stratified by the Japan Cancer of the Prostate Risk Assessment. The Japan Cancer of the Prostate Risk Assessment score is clinically useful as a predictor of the prognosis of prostate cancer treated with combined androgen blockade.",
keywords = "Combined androgen blockade, Outcome prediction, Prostate cancer",
author = "Yasuhide Kitagawa and Shiro Hinotsu and Kazuyoshi Shigehara and Kazufumi Nakashima and Shohei Kawaguchi and Hiroshi Yaegashi and Atsushi Mizokami and Hideyuki Akaza and Mikio Namiki",
year = "2013",
month = "7",
doi = "10.1111/iju.12037",
language = "English",
volume = "20",
pages = "708--714",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Japan cancer of the prostate risk assessment for combined androgen blockade including bicalutamide

T2 - Clinical application and validation

AU - Kitagawa, Yasuhide

AU - Hinotsu, Shiro

AU - Shigehara, Kazuyoshi

AU - Nakashima, Kazufumi

AU - Kawaguchi, Shohei

AU - Yaegashi, Hiroshi

AU - Mizokami, Atsushi

AU - Akaza, Hideyuki

AU - Namiki, Mikio

PY - 2013/7

Y1 - 2013/7

N2 - Objectives: The Japan Cancer of the Prostate Risk Assessment was developed as a risk stratification instrument for patients undergoing primary androgen deprivation therapy. However, there have been no studies to validate the accuracy of the Japan Cancer of the Prostate Risk Assessment in predicting clinical outcomes. We examined whether the clinical outcomes of patients treated with combined androgen blockade could be stratified using the Japan Cancer of the Prostate Risk Assessment. Methods: A total of 319 patients with prostate cancer treated with luteinizing hormone-releasing hormone agonist plus bicalutamide were included in this analysis. Progression-free survival, cause-specific survival and overall survival were compared among patients divided according to the prostate-specific antigen level at diagnosis, Gleason score on biopsy specimens, tumor-nodes-metastasis classification and Japan Cancer of the Prostate Risk Assessment score. Results: The median age of the patients was 75years, and the median prostate-specific antigen at diagnosis was 25.4ng/mL. A total of 102 patients (32.0%) had lymph node and/or distant metastases. On univariate analysis, the factors adopted in the Japan Cancer of the Prostate Risk Assessment points were significant predictors of progression-free survival. On multivariate analysis, clinical T stage and M stage were significant predictors of progression-free survival. The probabilities of progression-free survival and cause-specific survival were significantly different among the groups categorized according to the Japan Cancer of the Prostate Risk Assessment risk strata. The probability of overall survival in the low-risk group was higher than in the other groups. Conclusions: The progression-free survival, cause-specific survival and overall survival of prostate cancer patients treated by combined androgen blockade with bicalutamide were stratified by the Japan Cancer of the Prostate Risk Assessment. The Japan Cancer of the Prostate Risk Assessment score is clinically useful as a predictor of the prognosis of prostate cancer treated with combined androgen blockade.

AB - Objectives: The Japan Cancer of the Prostate Risk Assessment was developed as a risk stratification instrument for patients undergoing primary androgen deprivation therapy. However, there have been no studies to validate the accuracy of the Japan Cancer of the Prostate Risk Assessment in predicting clinical outcomes. We examined whether the clinical outcomes of patients treated with combined androgen blockade could be stratified using the Japan Cancer of the Prostate Risk Assessment. Methods: A total of 319 patients with prostate cancer treated with luteinizing hormone-releasing hormone agonist plus bicalutamide were included in this analysis. Progression-free survival, cause-specific survival and overall survival were compared among patients divided according to the prostate-specific antigen level at diagnosis, Gleason score on biopsy specimens, tumor-nodes-metastasis classification and Japan Cancer of the Prostate Risk Assessment score. Results: The median age of the patients was 75years, and the median prostate-specific antigen at diagnosis was 25.4ng/mL. A total of 102 patients (32.0%) had lymph node and/or distant metastases. On univariate analysis, the factors adopted in the Japan Cancer of the Prostate Risk Assessment points were significant predictors of progression-free survival. On multivariate analysis, clinical T stage and M stage were significant predictors of progression-free survival. The probabilities of progression-free survival and cause-specific survival were significantly different among the groups categorized according to the Japan Cancer of the Prostate Risk Assessment risk strata. The probability of overall survival in the low-risk group was higher than in the other groups. Conclusions: The progression-free survival, cause-specific survival and overall survival of prostate cancer patients treated by combined androgen blockade with bicalutamide were stratified by the Japan Cancer of the Prostate Risk Assessment. The Japan Cancer of the Prostate Risk Assessment score is clinically useful as a predictor of the prognosis of prostate cancer treated with combined androgen blockade.

KW - Combined androgen blockade

KW - Outcome prediction

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84880326462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880326462&partnerID=8YFLogxK

U2 - 10.1111/iju.12037

DO - 10.1111/iju.12037

M3 - Article

VL - 20

SP - 708

EP - 714

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 7

ER -